96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02517684
(ClinicalTrials.gov)
April 20151/7/2015Top-down Infliximab Study in Kids With Crohn's DiseaseTop-down Infliximab Study in Kids With Crohn's DiseaseCrohn's DiseaseDrug: Infliximab;Drug: Prednisolone;Other: Exclusive enteral nutrition;Drug: AzathioprineErasmus Medical CenterZonMw: The Netherlands Organisation for Health Research and Development;Hospira, now a wholly owned subsidiary of PfizerActive, not recruiting3 Years17 YearsAll100Phase 4Belgium;Finland;Netherlands;Denmark;Italy;Poland
2NCT01880307
(ClinicalTrials.gov)
January 20137/6/2013Infliximab Top-down in Pediatric CrohnInfliximab Top-down Study in Kids With Crohn's DiseaseCrohn's DiseaseDrug: Azathioprine;Drug: Infliximab;Drug: PrednisolonErasmus Medical CenterUniversity of Roma La Sapienza;University Hospital, BrusselsTerminated3 Years17 YearsBoth13Phase 4Italy;Netherlands
3EUCTR2008-005903-25-BG
(EUCTR)
23/04/201014/04/2010Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis) inflammatory bowel disease (Crohn’s disease and ulcerative colitis)
MedDRA version: 12.0;Level: LLT;Classification code 10021973;Term: Inflammatory bowel disease NOS
Product Name: SC12267
Product Code: SC12267
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
4SC AGNULLNot RecruitingFemale: yes
Male: yes
24Germany;Bulgaria
4EUCTR2008-005903-25-DE
(EUCTR)
08/01/200903/11/2008Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis) inflammatory bowel disease (Crohn’s disease and ulcerative colitis)
MedDRA version: 12.0;Level: LLT;Classification code 10021973;Term: Inflammatory bowel disease NOS
Product Name: SC12267
Product Code: SC12267
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
4SC AGNULLNot RecruitingFemale: yes
Male: yes
35Bulgaria;Germany
5NCT00609752
(ClinicalTrials.gov)
February 200824/1/2008Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's DiseaseAdverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's DiseaseCrohn DiseaseDrug: prednisolone;Dietary Supplement: Alicalm (polymeric liquid formula)University Hospital BirminghamSHS International;Children's Memorial Research Foundation;St George's University Hospital Research FoundationRecruiting7 Years17 YearsBoth80Phase 4United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2006-003870-88-DE
(EUCTR)
27/11/200629/09/2006A Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (COSPAR I). - COSPAR IA Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (COSPAR I). - COSPAR I In the present study, the corticosteroid-sparing effect of certolizumab pegol will be assessed in patients with moderate to severe Crohn’s disease who have received initial acute corticosteroid therapy (prednisone or prednisolone) for induction of remission.
MedDRA version: 8.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Product Name: certolizumab pegol
Product Code: CDP870
INN or Proposed INN: certolizumab pegol
UCB Pharma S.A.NULLNot RecruitingFemale: yes
Male: yes
352Phase 3bGermany
7EUCTR2005-003337-40-GB
(EUCTR)
13/02/200613/01/2006Autologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial) - ASTICAutologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial) - ASTIC Patients with Crohn's disease who have not responded to immunosupressant medicationProduct Name: Cyclophosphamide
Product Code: N/A
INN or Proposed INN: cyclophosphamide
Other descriptive name: N/A
INN or Proposed INN: cyclophosphamide
Other descriptive name: N/A
Product Name: Filgrastim
Product Code: N/A
INN or Proposed INN: Filgrastim
Other descriptive name: N/A
Product Name: rabbit antithymocyte globulin
Product Code: rbATG
INN or Proposed INN: rabbit antithymocyte globulin
Other descriptive name: N/A
Product Name: Mesna
Product Code: N/A
INN or Proposed INN: mensa
Other descriptive name: N/A
Product Name: methyl prednisolone
Product Code: N/A
INN or Proposed INN: methyl prednisolone
Other descriptive name: N/A
Product Name: ciprofloxacin
Product Code: N/A
INN or Proposed INN: ciprofloxacin
Other descriptive name: N/A
European Group for Blood and Marrow Transplantation (EMBT)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48United Kingdom
8NCT00265772
(ClinicalTrials.gov)
November 200514/12/2005Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular BasisPhase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular BasisCrohn's Disease;PediatricDrug: MODULEN IBD (R) (specific Enteral Nutrition);Drug: prednisolonHôpital Necker-Enfants MaladesInstitut National de la Santé Et de la Recherche Médicale, France;NestléRecruiting6 Years18 YearsBoth24Phase 4France
9NCT00796250
(ClinicalTrials.gov)
November 1, 200321/11/2008Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)Efficacy of Infliximab as Bridging Therapy in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With AzathioprineCrohn's DiseaseBiological: Infliximab;Drug: AZA;Drug: Placebo Prednisolone;Drug: Prednisolone;Biological: Placebo InfliximabMerck Sharp & Dohme Corp.NULLTerminated18 Years65 YearsAll9Phase 3NULL